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Abstract - Hepatitis C virus infection is the most common chronic blood-borne infection and one of the most important 
causes of chronic liver disease. Knowing the predictors associated with pegylated interferon/ribavirin (PEG-IFN/RBV) 
combination therapy response is important for evidence-based treatment recommendations. The goal of this study was 
to identify host and viral factors of response to PEG-IFN/RBV treatment in chronic hepatitis C genotype 1b patients. We 
have examined the relationship between gender, age, level of alanine aminotransferase (ALT), viral load and liver fibrosis 
progression on therapy response. ALT level and viral load were evaluated before starting treatment with combination 
therapy. The elevated levels of ALT and route of HCV transmission were found to be significantly associated with the re-
sponse to therapy in HCV-infected patients. Our findings may be useful for estimating a patient’s likelihood of achieving 
sustained viral response.
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INTRODUCTION
Chronic hepatitis C virus (HCV) infection is a global 
health problem affecting more than 180 million peo-
ple worldwide, or approximately 3% of the human 
population (WHO, 1999). Chronic HCV infection 
frequently results in liver cirrhosis and is associated 
with an elevated risk of developing hepatocellular 
carcinoma (HCC) (Giannini et al., 2003). Until re-
cently, pegylated interferon/ribavirin (PEG-IFN/
RBV has been the standard of care treatment for all 
hepatitis C genotypes, resulting in viral eradication in 
approximately 50% of treated patients with the HCV 
genotype 1 (Bridge and Sawilowsky, 1999; Brown and 
Gaglio, 2003). The recent addition of first-generation 
protease inhibitors to PEG-IFN/RBV combination 
therapy improved antiviral efficacy but increased 
the side effects, especially severe anemia (Kumada et 
al., 2012; McHutchison et al., 2009a). The increased 
healthcare costs associated with the addition of pro-
tease inhibitors will confine triple therapy usage in 
many countries with limited sources. Moreover, in 
patients with favorable predictors for SVR (low pre-
treatment HCV RNA, IL28 polymorphisms, no ad-
vanced fibrosis), dual therapy with PEG-IFN/RBV 
may still be a choice (Mauss et al, 2012). For the rea-
sons mentioned previously, considering the factors 
associated with PEG-IFN/RBV combination therapy 
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outcome is still important for evidence-based treat-
ment recommendations for chronic HCV patients. 
Sustained viral response (SVR), the primary goal of 
therapy, is defined as undetectable HCV RNA for at 
least 24 weeks post treatment (Donlin et al., 2007). 
Multiple factors including virus-specific characteris-
tics such as viral load, genotype, viral variants within 
the interferon sensitivity determining region (ISDR), 
may be responsible for these differences, but also 
clinical and epidemiological features are connected 
with a response to the PEG-IFN/RBV combination 
therapy (Feld and  Hoofnagle, 2005; Kau et al., 2008; 
Wohnsland et al., 2007). Host genetic polymorphisms 
of several genes such as chemokines, interleukins and 
interferon-stimulated genes are associated with SVR 
(Asselah et al., 2007; Kau et al., 2008; Wohnsland et 
al., 2007). The aim of this study was to identify host 
and viral factors of response to pegylated interferon-
alfa/ribavirin treatment in chronic hepatitis C pa-
tients from Serbia, infected with genotype 1b, the 
most frequent genotype in Serbia (Stamenkovic et 
al., 2000).
MATERIALS AND METHODS
Patients
Samples were collected from 100 chronic hepatitis C 
patients before start of treatment with combined an-
tiviral therapy (pegylated interferon-alfa/ribavirin). 
Samples of patients from Serbia were classified ac-
cording to the outcome of therapy (50 SVR and 50 
NR – non-responders). All patients were registered 
randomly in the Clinical Center of Serbia and the 
Military Medical Academy in Belgrade. Patients re-
ceived pegylated interferon-alfa (180 μg/week) plus 
ribavirin (800 mg/d) for 24 weeks (HCV genotype 
2 and 3) or pegylated interferon-alfa (180 μg/week) 
plus ribavirin (1000 mg/d, if their body weight was 
<75 kg, or 1200 mg/d, if it was ≥75 kg) for 48 weeks 
in patients with HCV genotypes 1 or 4. A sustained 
virologic response was defined as the absence of HCV 
RNA (<250 IU/ml) in serum 6 months after the end 
of treatment. Non-response was defined as the pres-
ence of serum HCV RNA (<250 IU/ml) 6 months 
after the end of treatment. Histological findings were 
evaluated according to the stage of fibrosis (F0-F3) 
and cirrhosis (F4) by METAVIR score. Liver histo-
logical staging was based on five degrees of fibrosis as 
F0 (no fibrosis), F1 (mild fibrosis without septa), F2 
(moderate fibrosis with few septa), F3 (severe fibrosis 
with numerous septa without cirrhosis) and F4 (cir-
rhosis). These stages were further grouped as F0-F1 
(no/minimal fibrosis), F2-F3 (advanced fibrosis) and 
F4 (cirrhosis). Biochemical analyses were performed 
at the hospital laboratory by standard procedure. 
Plasma samples were prepared from the patients be-
fore starting therapy. All patients were positive for 
the antibody to HCV and had a history of raised se-
rum ALTs for more than 6 months. The study was 
approved by the Ethics Committee of the Faculty of 
Medicine, University of Belgrade, and all patients 
provided written consent. 
RNA Extraction
Total RNA was extracted from 100 µl of plasma us-
ing the Ribo-Sorb-100 (HCV Quant) RNA/DNA 
Extraction Kit (Sacace biotechnologies, Como, Italy) 
and dissolved in 50μL of RNA-eluent according to 
the manufacturer’s protocol. The RNA obtained was 
stored at -20° C until use.
RT-PCR and amplification 5’ non translated-region 
(5’NTR)
The total RNA-HCV was detected by (reverse tran-
scription) RT-PCR. Reverse transcription and first 
PCR was performed using a QIAGEN One Step RT-
PCR Kit (Qiagen, GmbH, Germany), according to 
the manufacturer’s instructions. The selected part 
of the 5’ NTR was amplified by RT-PCR (QIAGEN 
One Step RT-PCR Kit, Germany) with sense and 
antisense primers (IR-F ggcgacactccaccatagat: IR-R 
cacggtctacgagacctccc), which covered 319 nt. We car-
ried out RT-PCR for 35 cycles (reverse transcription 
at 50°C for 30 min and at 95°C for 15 min), followed 
by amplification at 94°C for 45 s, 54°C for 45 s and 
72°C for 60 s, with a 7 min final extension at 720C. 
The amplified first round PCR products were sub-
jected to two second rounds of PCR amplifications. 
In the second PCR, the same primers were used as in 
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RT-PCR with 0.5 U/reaction Dream Taq polymerase 
(Fermentas, Lithuania). The amplification protocol 
included initial denaturation for 3 min at 95oC fol-
lowed by 28 cycles of amplification at 94°C for 45 s, 
58°C for 45 s and 72°C for 60 s, with a 7 min final 
extension at 720C (thermal cycler Applied Biosys-
tems Gene Amp® PCR System 9700). The final PCR 
products were analyzed on an 8% polyacrylamide gel 
stained with silver nitrate and the 319-bp band was 
confirmed. 
Quantitative detection of HCV RNA
The levels of HCV RNA were determined by real-
time PCR (Applied Biosystems 7500, Foster City, 
USA) with the commercially available assay R-TMQ 
HCV Kit (Sacace Biotechnologies, Como, Italy) ac-
cording to the manufacturer’s instructions. 
HCV Genotyping
The genotype of HCV was determined with the (re-
verse transcription) RT-PCR HCV (HCV Genotype 
Kit, Sacace Biotechnologies, Como, Italy) according 
to the manufacturer’s instructions (thermal cycler 
Applied Biosystems Gene Amp® PCR System 9700). 
Statistical analysis
Differences in frequency distribution between two 
or more categorical variables were done by Pearson’s 
χ2 test. Normality of the continuous variables was 
tested by Kolmogorov-Smirnov test with Lilliefors’ 
correction. Means of normally distributed continu-
ous variables between sustained virologic respond-
ers and non-responders were compared by unpaired 
t-test and means of skewed continuous variables 
with nonparametric Mann-Whitney U Test. Results 
are presented as mean ± standard deviation (SD). 
The correlation between ALT levels and RNA vi-
ral load was tested by Spearman’s rank order cor-
relation test. In all tests, p values of less than 0.05 
were considered statistically significant. Statistical 
analysis was performed using Statistica Version 8.0 
software package (StatSoft Inc, 2007) and Microsoft 
Excel 7.0.
RESULTS
The current study included only patients with HCV 
genotype 1b divided according to therapy outcome 
into two groups (50 SVR and 50 NR). The baseline 
characteristics of the patients overall and divided 
by response to therapy are shown in Table 1. There 
were no significant differences between the SVR and 
NR groups concerning age and gender (Table 1). 
Both groups had serum ALT levels above the upper 
limit of normal (>30 U/L), but the ALT level in the 
NR group was significantly higher than that in the 
SVR group of patients (p = 0.046). Further statistical 
analysis showed that elevated ALT levels were cor-
related with viral load (Spearman’s r = 0.21, p = 0.04) 
(Fig. 1). However, we found no correlation between 
the stage of liver fibrosis and response to therapy (p 
= 0.76) or baseline clinical features of the patients 
(p = 0.57, data not shown). In our sample, fibrosis 
progression was independent of genotype, ALT level, 
pre-treatment viral load and response to therapy. 
Histologically, 33% of all the patients had moderate 
fibrosis (F2) and 27% showed evidence of cirrhosis 
(F4) (Table1). The effect of pre-treatment viral load 
on the response to therapy was also studied. Patients 
with SVR had a slightly lower pre-treatment viral 
load compared to those with NR, but the difference 
was not statistically significant (Table 1). Moreover, 
pre-treatment levels of viral load had no effect on 
liver histology (p = 0.93, data not shown). The major 
route of HCV transmission among our patients over-
all was unknown (45%), followed by blood transfu-
sion (25%), intravenous drug use (IVDU) (18%), 
previous surgery (7%), hemodialysis (4%) and high 
risk professional activity (1%) (Table 1). There were 
significant differences between the groups of patients 
concerning route of HCV transmission and response 
to antiviral therapy (p = 0.02). With regard to re-
sponse, the unknown route of HCV transmission 
and transmission by IVDU were significantly more 
frequent in the patients exhibiting SVR than among 
the non-responders. On the other hand, a history 
of HCV transmission by blood product transfusion 
and hemodialysis were significantly more common 
in NR patients than in those with SVR (Table 1). In 
addition, intravenous drug users were significantly 
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younger than patients with a history of blood trans-
fusion and those with an unknown route of HCV 
transmission (mean age ± SD: 33.6 ± 7.4 vs. 42.6 ± 
12.3 vs. 45.0 ± 11.8, respectively, ANCOVA post-hoc 
LSD test p = 0.03, adjusted for gender). With regard 
to gender, men were significantly more common in 
the group of intravenous drug users than women 
(83% vs. 17%, p<0.0001).
DISCUSSION
Although HCV infection resolves spontaneously in 
some patients, about 85% of them develop chronic 
infection and represent potential candidates for an-
tiviral therapy (Marcellin, 1999; Liang et al., 2000). 
To predict the treatment response before starting an-
tiviral treatment it is important to consider baseline 
factors associated with SVR to PEG-IFN/RBV, such 
as HCV genotype, degree of liver fibrosis, pre-treat-
ment viral load, age, gender and ethnicity. Accord-
ing to current recommendations, HCV genotype and 
pre-treatment viral load are the only parameters rel-
evant for an estimation of treatment duration (Gh-
any et al., 2009; McCaughan et al., 2007; Zeuzem et 
al., 2009). There is a wealth of evidence for age as 
an important host factor in the treatment response. 
Some large prospective studies showed that age cor-
related significantly with SVR and patients younger 
than 40-45 years had the best response rates (Fried 
et al., 2002; Manns et al., 2001; Poynard et al., 2000). 
Considering the above-mentioned, we observed that 
younger patients had slighter higher response rates 
to antiviral therapy than older ones, but the differ-
ence was not statistically significant, which confirms 
earlier findings (Fried et al., 2002; Hadziyannis et al., 
2004; Manns et al., 2001;  McHutchison et al., 2009b; 
Zeuzem et al., 2004). It has been demonstrated that 
patients with normal ALT levels have a similar viro-
logic response to interferon therapy as patients with 
elevated ALT levels (Gordon et al., 2000; Rossini 
et al., 1997; Van Thiel et al., 1995). In contrast, we 
found that ALT level was significantly higher in NR 
than in SVR patients. Both groups of patients had se-
rum ALT above the upper limit of normal, and one 
Fig. 1. Spearman correlation of ALT levels and viral load in HCV patients. Elevated levels of serum ALT were significantly associated 
with pre-treatment viral load (p<0.05).
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possible explanation is that younger patients were 
enrolled in our study and higher ALT levels were re-
ported to be associated with an active host immune 
response to viral populations and rapid elimination 
of the infected hepatocytes (Bozdayia et al., 2000; 
Gavazzi and Krause, 2002; Gordon et al., 2000; Uto 
et al., 2012). An elevated ALT level acts as an indica-
tor of hepatocyte injury (Murakami et al., 2004; Ong 
et al., 1999). We found no significant difference be-
tween increased serum ALT and stage of liver fibro-
sis (p = 0.93), which is in line with the observation 
of Puoti and colleagues (1997), while Zechini et al. 
(1994) detected a correlation between serum ALT 
level and liver damage. With respect to virus-related 
factors, HCV pre-treatment viral load has been sug-
gested as a predictor of SVR (Ijaz et al., 2011; Manns 
et al., 2001; Salmerón et al., 2008). In addition, only 
the pre-treatment viral load was observed to be es-
sential for successful standard antiviral therapies 
(Berg et al., 2000; Fried et al., 2002; Izumi et al., 2010; 
Table 1. Baseline clinical features of HCV genotype 1b patients according to response to therapy.
Clinical and pathological characteristics of 
patients
Sustained responders
(n = 50)
Non-responders
(n = 50)
HCV patients overall
Value ± SD p
Age (years) a 40.44 ± 11.78 43.74 ± 12.31 42.09 ± 12.10 ns*
Sex, n (female/male) 22/28 22/28 44/56 ns
ALT level (U/L) a 80.88 ± 56.88 92.62 ± 46.54 86.75 ± 52.04 0.046#
HCV RNA level (IU/mL) c 463522.0 ± 662955.7 749411.2 ± 1635497.7 606466.6 ± 1249837.0 ns#
Transmission of HCV infection n (%) n (%) Alln (%)
Unknown 27 (54) 18 (36) 45 (45) <0.005
Post-transfusion 8 (16) 17 (34) 25 (25) <0.005
Hemodialysis 0 4 (8) 4 (4) <0.005
Intravenous drug use 12 (24) 6 (12) 18 (18) <0.025
Previous surgery 2 (4) 5 (10) 7 (7) ns
High risk professional activity 1 (2) 0 1 (1) ns
Stage of fibrosis b n (%) n (%) Alln (%)
F0 3 (6) 4 (8) 7 (7) ns
F1 9 (18) 9 (18) 18 (18) ns
F2 19 (38) 14 (28) 33 (33) ns
F3 8 (16) 7 (14) 15 (15) ns
F4 11 (22) 16 (32) 27 (27) ns
a- data expressed as mean ± SD; b- stage of fibrosis expressed by METAVIR score (fibrosis 0, 1, 2, 3, and cirrhosis 4); c- expressed HCV 
RNA level x 105 IU/mL; comparison was done between sustained responders and non-responders: p - for categorical variables Pearson 
Chi square test was used; *- comparison of normally distributed continuous variables between sustained responders and non-respond-
ers using Students’ t-test; #-comparison of skew distributed continuous variables between sustained responders and non-responders by 
Mann-Whitney U test; -p- values < 0.05 were considered statistically significant; ns-not statistically significant.
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Manns et al., 2001). In our study, average viral loads 
were higher in non-responders, but differences were 
not significant, which is in accordance with earlier 
results (Araújo et al., 2002; Idrees et al., 2009; Izumi 
et al., 2010; Kanai, 1992; Lau, 1993; Shiffman et al., 
2007; Zuberi et al., 2008). We found no statistically 
significant differences between pre-treatment vi-
ral load and stage of liver fibrosis, which confirms 
some previous results (Kao et al., 1996; Zeuzem et al., 
1996), but does not comply with the finding of a sig-
nificant correlation between serum HCV RNA titer 
and liver damage (Fanning et al., 1999). While some 
authors noted no evidence of correlation between se-
rum viral load and ALT (Fanning et al., 1999; Liu et 
al., 2009), they did find a significant association with 
the rate of high ALT levels (ALT>40U/L), which is 
in line with our observation of a high average ALT 
concentration. In agreement with others, the cur-
rent study revealed a significant difference between 
route of HCV transmission and age (Cornberg et al., 
2011; Gheorghe et al., 2008; Nemecek and Strunecky, 
2009). We also investigated the relationship between 
route of transmission and sex. We found that men 
were more frequent in the group of intravenous drug 
users than women were, but among patients with a 
positive history blood transfusion, there were con-
siderably more women than men, which is in accord-
ance with the large epidemiological study of Corn-
berg et al. (2011). Moreover, we found significant 
differences between several routes of HCV transmis-
sion and response to therapy. Unknown routes of 
HCV transmission and transmission by intravenous 
drug use were significantly more frequent in the SVR 
than in NR patients. On the other hand, a history 
of blood product transfusion and the hemodialysis 
route of HCV transmission were more common in 
NR than in SVR patients. These findings may suggest 
that infectious dose and route of infection could be 
connected with different responses to therapy. In the 
Serbian population, the unknown route of transmis-
sion is dominant (Cornberg et al., 2011). It has been 
suggested that the high proportion of cases with an 
unknown transmission route could be partly due to 
delay between infection and diagnosis, or the result 
from other common exposures (such as nosocomi-
al transmission); it may also reflect the individual’s 
desire not to disclose delicate information (Chaves 
et al., 2003). Other significant risk factors for HCV 
transmission in the population of Serbia were trans-
fusion and intravenous drug use. Similar observa-
tions were obtained in some earlier epidemiological 
studies (Alter, 2007; Cornberg et al., 2011). Some 
host factors previously associated with treatment 
failure, such as advanced age, advanced liver fibrosis 
stage and cirrhosis, did not reach statistical signifi-
cance in our study. These discrepant results may be 
due to one or more factors. The first is probably relat-
ed to the case control study design matched for age, 
sex, genotype and response to therapy. The second 
may be connected to the relatively small number of 
enrolled patients. However, the present investigation 
has demonstrated that pre-treatment viral load, ALT 
level and route of HCV transmission are important 
factors in the response to therapy, but should not be 
used alone to predict disease outcome. Further re-
search ought to include comparative analysis of hu-
man and viral genome specificity with special focus 
on the polymorphism of genes participating in the 
human immune response, such as IL28B.
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